We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.

Targeting PDE4 drives anti-inflammatory and antifibrotic effects, and Boehringer has been working on its own PDE4 inhibitor ...

Palisade Bio (NASDAQ:PALI) just reported results for the second quarter of 2024. Palisade Bio reported earnings per share of -$3.32. This was below the analyst estimate for EPS of -$2.93.

Earnings Estimate Revisions for Palisade Bio This company is expected to earn -$11.40 per share for the fiscal year ending December 2024, which represents a year-over-year change of 57.8%.

06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI ...

Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio ...

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes ...

Palisade Bio is fortifying its brand image. The California-based biotech unveiled a new logo and website design, while also doubling down on its commitment to advancing its lead candidate in ...